The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma

Hypertension Research

Volumn 35, Issue 1, 2012, Pages 123-125

  Krysiak, Robert ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CYTOKINE; EPLERENONE; FLUDROCORTISONE; GAMMA INTERFERON; HYDROCHLOROTHIAZIDE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PRAZOSIN; RENIN; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ABDOMINAL RADIOGRAPHY; ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONOMA; ANTIHYPERTENSIVE THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LAPAROSCOPIC SURGERY; LETTER; LYMPHOCYTE; MONOCYTE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; ADULT; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTES; MONOCYTES; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 84855469877     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.142     Document Type: Letter

References (10)

1. Young W. Primary aldosteronism: renaissance of the syndrome. Clin Endocrinol 2007; 66: 607-618.
2. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Hemost 2009; 7(Suppl 1): 328-331.
3. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
4. Kher N, Marsh JD. Pathobiology of atherosclerosis-a brief review. Semin Thromb Hemost 2004; 30: 665-672.
5. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006; 4: 205-213. (Pubitemid 46785488)
6. Okopieñ B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Herman ZS. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 2005; 46: 377-386. (Pubitemid 41262842)
7. Okopieñ B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Labuzek K, Herman ZS. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004; 176: 327-335. (Pubitemid 39369523)
8. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918. (Pubitemid 350287534)
9. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85.
10. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645. (Pubitemid 43882339)